Advertisement Sidebar
Recent Posts
- NATERA GALAXY Study Links ctDNA Status to Survival & Treatment Response ESMO 2024
- FDA approves KEYTRUDA® / Pembrolizumab with Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma SLIDES
- SLIDES: FDA Approves Kisqali / Ribociclib for Early High-Risk Breast Cancer
- VIDEO: iTeos and GSK’s TIGIT Combination Therapy Shows Significant Promise at ESMO 2024
- VIDEO: FDA Approves Atezolizumab / Tecentriq Hybreza For Subcutaneous PD-(L)1 Cancer Immunotherapy in NSCLC
Oncology Conference Videos
Oncology News
In this ASH 2023 interview, Dr. Jos Melenhorst discusses a collaborative study on single-cell multi-omics…
By. Joanne Kotsopoulos, MD, Date: 12/07/2023 At the SABCS 2023 conference, Joanne Kotsopoulos, MD, a researcher…
By. Saranya Chumsri, MD Date: 12/12/2023 Saranya Chumsri, MD, an expert in the field of…
Evandro Bezerra, MD, hematologist and assistant professor at The Ohio State University Wexner Medical Center,…
By. Ruth O’Regan MD Date: 12/07/2023In an interview, Ruth O’Regan MD addresses questions related to the…
By. Valeria Santini, MDDate: 12/13/2023At the ASH 2023 symposium, Valeria Santini, MD, a distinguished medical…
Under the lights of ASH 2023, the microphone poised to capture insights, Dr. Lorenzo Falchi,…
Zandra Klippel, MD, Global Product Head, Sanofi – Phase 3 IsKia trial of Sarclisa® (isatuximab)…
In the groundbreaking study conducted by Bruce Feinberg,DO, Chief Medical Officer at Cardinal Health, the…
Catherine Diefenbach, MD, a Hematologist and Medical Oncologist at NYU Langone Health, led a study…
Introduction to Myelofibrosis and JAK Inhibitors Myelofibrosis, a complex myeloproliferative neoplasm, presents a unique set…